ACCA Strategic Professional · Strategic Business Leader · Managing, monitoring and mitigating risk
Hadley Pharma sells a product in a country where a new law may ban it. Management estimates a 10% chance of a ban, with a loss of $50 million if it happens. The board decides not to lobby or insure and instead budgets $5 million as an expected cost. Which description best fits the board's decision?
This is risk acceptance. The board calculates an expected loss of $5 million (10% x $50 million) and budgets for it without reducing, transferring or avoiding the exposure, so the company itself retains the risk.
- ARisk acceptance, using expected value to quantify the exposureCorrect
- BRisk transfer, because a cost has been budgeted
- CRisk avoidance, because the exposure has been measured
- DRisk sharing, because the cost is spread over the budget
Explanation
Expected loss is 10% x $50m = $5m. The board takes no action to reduce, transfer or avoid, and budgets for the loss, which is risk acceptance. Budgeting is not transfer since no third party bears the loss, and measuring a risk is not avoiding it.
Did you get it right without looking?
One question tells you little. A timed set on Managing, monitoring and mitigating risk shows your real accuracy, how long you take and where you lose marks.
More Managing, monitoring and mitigating risk questions
- Kestrel Foods, a listed manufacturer, buys most of its wheat from one region. A drought there causes a sharp rise in input prices, and the b…
- Wexmoor Energy's board reviews its risk management and internal control systems annually and reports on this to shareholders. Which statemen…
- Norvik Airlines is considering launching a route to a country with a rising risk of political unrest. The board assesses the risk as high li…
- Halden Energy's board sets a risk appetite statement that tolerates high risk in new-market ventures but none for safety breaches. Business …
- Olwen Retail has set a risk appetite statement saying it will accept only low levels of regulatory and reputational risk but is willing to t…
- Orlan Pharma plans to outsource its clinical trial data processing to a specialist firm, reasoning that this will 'transfer' the risk of dat…